Search Within

Victoria Falco

Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
Groups
  1. Nursing (6)
  2. Adult Leukemia (5)
  3. Center for Hematologic Malignancies (5)
  4. Department of Medicine (5)
  5. Hematologic Malignancies, Division of (5)
  6. Advanced Practice Providers (3)

More Groups

People
  1. Jae Park (5)
  2. Gail Panton (4)
  3. Sonia Lebowitz (4)
  4. Andrew Zelenetz (3)
  5. Anthony Mato (3)
  6. Lindsey Roeker (3)

More People

Years
  1. 2023 (2)
  2. 2022 (2)
  3. 2021 (2)
Publications
  1. Blood (3)
  2. Clinical Cancer Research (1)
  3. NEJM Evidence (1)
  4. Oncology Nursing Forum (1)
Publishers
  1. American Society of Hematology (3)
  2. American Association for Cancer Research (1)
  3. Massachusetts Medical Society (1)
  4. Oncology Nursing Society (ONS) (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of minimal residual disease (MRD)-adapted front line venetoclax and obinutuzumab in fit patients with chronic lymphocytic leukemia (CLL): Effect of obinutuzumab on tumor lysis syndrome (TLS) risk and safety of outpatient venetoclax dose escalation
    Meeting Abstract

    Roeker, L. E.; Zelenetz, A. D.; Park, J. H.; Derkach, A.; Geyer, M. B.; Islam, P.; Falchi, L.; Palomba, M. L.; Kumar, A.; Salles, G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Vemurafenib and obinutuzumab as frontline therapy for hairy cell leukemia
    Journal Article

    Park, J. H.; Devlin, S.; Durham, B. H.; Winer, E. S.; Huntington, S.; von Keudell, G.; Vemuri, S.; Shukla, M.; Falco, V.; Cuello, B.; more...
    NEJM Evidence (2023)

    Fulltext@MSK | Save
  • Adding umbralisib and ublituximab (U2) to ibrutinib in patients with CLL: A phase II study of an MRD-driven approach
    Journal Article

    Roeker, L. E.; Feldman, T. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Dorsey, C.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Straus, D. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease (MRD)-driven, time-limited approach
    Meeting Abstract

    Dorsey, C.; Falco, V.; Pena-Velasquez, C.; Lebowitz, S.; Purdom, M.; Panton, G.
    Oncology Nursing Forum (2022)

    Fulltext@MSK | Save
  • A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease(MRD)-driven, time-limited approach
    Meeting Abstract

    Roeker, L. E.; Leslie, L. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Pena-Velasquez, C.; Lebowitz, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • First line chemo-free therapy with the BRAF inhibitor vemurafenib combined with obinutuzumab is effective in patients with HCL
    Meeting Abstract

    Park, J. H.; Winer, E. S.; Huntington, S. F.; von Keudell, G.; Vemuri, S.; Shukla, M.; Kinoshita, J. C.; Falco, V.; Gore, S. D.; Stone, R. M.; more...
    Blood (2021)

    Fulltext@MSK | Save